Suguru Ueno

Suguru Ueno is an experienced professional in investment management and biopharmaceuticals, currently serving as Principal at JAFCO since April 2025. Prior to this role, Suguru held a position as Joint Visiting Scholar at Stanford University from March 2023 to March 2025. From April 2011 to March 2025, Suguru worked at Daiichi Sankyo Co., Ltd., where contributions included serving as a Scientist in the Cell Therapy Lab focused on regenerative therapy and as Associate Manager leading the global project for U3-1402, an anti-HER3 antibody drug conjugate. Earlier, Suguru was a Scientist at U3 Pharma GmbH with a focus on target discovery and preclinical pharmacology for the same project. Academic qualifications include a Ph.D. in Pharmaceutical Sciences from The University of Tokyo and a Bachelor of Science in Biology from Osaka University. An intensive English program in Business English was completed at OISE language school in London in 2013.